Impact of fenofibrate on type 2 diabetes patients with features of the metabolic syndrome: Subgroup analysis from FIELD

Current Cardiology Reviews

Volumn 6, Issue 2, 2010, Pages 112-118

  Hermans, Michel P ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Cardiovascular risk; Fenofibrate; Metabolic syndrome; PPAR agonists; Type 2 diabetes

Indexed keywords

FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROGENIC DYSLIPIDEMIA; CARDIOVASCULAR RISK; DYSLIPIDEMIA; HUMAN; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW;

EID: 77951528086     PISSN: 1573403X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340310791162686     Document Type: Review

References (36)

1. National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002; 17: 3143-3221
2. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007; 14 Suppl 2: S1-113.
3. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278
4. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433-438
5. International Diabetes Federation. IDF worldwide definition of the metabolic syndrome. http://www.idf.org/webdata/docs/MetSyndrome-FINAL.pdf (accessed 4 November 2009).
6. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-689
7. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 2004; 27: 2444-2449
8. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 2005; 28: 2745-2749
9. Cull CA, Jensen CC, Retnakaran R, Holman RR. Impact of the metabolic syndrome on macrovascular and microvascular outcomes in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study 78. Circulation 2007; 116: 2119-2126
10. Scott R, O'Brien R, Fulcher G, et al. The effects of fenofibrate treatment on cardiovascular disease risk in 9795 people with type 2 diabetes and various components of the metabolic syndrome: the FIELD study. Diabetes Care 2009; 32: 493-498
11. Watson KE, Horowitz BN, Matson G. Lipid abnormalities in insulin resistant states. Rev Cardiovasc Med 2003; 4: 228-236
12. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990; 82: 495-506.
13. Bruckert E, Baccara-Dinet M, Eschwege E. Low HDL-cholesterol is common in European Type 2 diabetic patients receiving treatment for dyslipidaemia: data from a pan-European survey. Diabet Med 2007; 24: 388-391
14. Bruckert E, Baccara-Dinet M, McCoy F, Chapman J. High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients. Curr Med Res Opin 2005; 21: 1927-1934
15. Mulè G, Cerasola G. The metabolic syndrome and its relationship to hypertensive target organ damage. J Clin Hypertens 2006; 8: 195-201.
16. Sarti C, Gallagher J. The metabolic syndrome: prevalence, CHD risk, and treatment. J Diabetes Complications 2006; 20: 121-132
17. Ford ES. Risks for all-cause mortality, cardiovascular disease and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005; 28: 1769-1778
18. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middleaged men. JAMA 2002; 288: 2709-2716
19. Bonadonna RC, Cucinotta D, Fedele D, Riccardi G, Tiengo A. The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes: results from Metascreen, a multicenter diabetes clinic-based survey. Diabetes Care 2006; 29: 2701-2707
20. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28: 2289-2304. (Pubitemid 41242486)
21. Grundy SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds J Am Coll Cardiol 2006; 47: 1093-1100.
22. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidaemia, inflammation, and atherosclerosis. Pharmacol Rev 2006; 58: 342-374
23. Wong J, Molyneaux L, Constantino MI, Twigg SM, Yue DK. The metabolic syndrome in type 2 diabetes: when does it matter? Diabetes Obes Metab 2006; 8: 690-697
24. Plutzky J. PPARs as therapeutic targets: reverse cardiology? Science 2003; 302: 406-474
25. Marx N, Kehrle B, Kohlhammer K, et al. PPAR activators as antiinflammatory mediators in human T lymphocytes. Implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res 2002; 90: 703-710
26. Kon Koh K, Yeal Ahn J, Hwan Han S, et al. Effects of fenofibrate on lipoproteins, vasomotor function, and serological markers of inflammation, plaque stabilization, and hemostasis. Atherosclerosis 2004; 174: 379-383
27. Keating GM, Croom KF. Fenofibrate. A review of its use in primary dyslipidemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs 2007; 67: 121-153
28. Muhlestein JB, May HT, Jensen JR, et al. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR study. J Am Coll Cardiol 2006; 48: 396-401.
29. Rizzo M, Berneis K. The clinical significance of the size of lowdensity- lipoproteins and the modulation of subclasses by fibrates. Curr Med Res Opin 2007; 23: 1103-1111 (Pubitemid 46799594)
30. May HT, Anderson JL, Pearson RR, et al. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study). Am J Cardiol 2008; 101: 486-489
31. Ziouzenkova O, Perrey S, Asatryan L, et al. Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an anti-inflammatory role for lipoprotein lipase. Proc Natl Acad Sci USA 2003; 100: 2730-2735
32. Okopień B, Krysiak R, Herman ZS. Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance. J Clin Endocrinol Metab 2006; 91: 1770-1778
33. FIELD Study Investigators. The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Cardiovasc Diabetol 2004; 3: 9.
34. FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849-1861.
35. Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007; 370: 1687-1697
36. Rajamani K, Colman PG, Li LP, et al. On behalf of the FIELD study investigators. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 2009; 373: 1780-1788.